Eli Lilly

NVIDIA office Paris
#Artificial intelligence (AI) #Collaboration #Drug discovery #Eli Lilly #JP Morgan Healthcare Conference #NVIDIA #Thermo Fisher Scientific

NVIDIA expands drug discovery platform, partners with Lilly

NVIDIA has announced a major expansion of NVIDIA BioNeMo, its open development platform for AI-driven biology and drug discovery, at the JP Morgan Healthcare Conference.  The platform has expanded to include:  New NVIDIA Clara open models, the RNAPro model for RNA structure prediction and the ReaSyn v2 model  BioNeMo Recipes… Read More

#Business & Investment #News #Trending News

#Eli Lilly #Metabolic diseases #Nimbus #Obesity

Nimbus partners with Lilly on novel obesity treatment 

Drug discovery company Nimbus Therapeutics has partnered with Eli Lilly to develop a novel oral treatment for obesity and other metabolic diseases.  The companies aim to apply Nimbus’ computational chemistry and structure-based drug design approach to an early-stage, small molecule discovery programme addressing a significant unmet need in obesity.  This… Read More

#Business & Investment #News

#Eli Lilly #GLP-1 #Obesity #Phase III trial #Weight loss

Oral GLP-1 helps patients maintain weight loss after injectables

Lilly’s orforglipron has helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase III trial.  The ATTAIN-MAINTAIN trial evaluated orforglipron, a once-daily oral glucagon-like peptide-1 (GLP-1) receptor agonist, for weight maintenance over 52 weeks after initial treatment for 72 weeks… Read More

#Editor's Choice #News

#AI #Allergen immunotherapy #Allergy #Alzheimer's #Biotech #China #Clinical trial #DDW Highlights podcast #Eli Lilly #Obesity #Osteoarthritis #Spinogenix

DDW Highlights: 16 December 2025

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, innovative treatments showed potential to treat neurodegenerative diseases, allergies and arthritis. Elsewhere,… Read More

#Podcasts

#AI #Allergen immunotherapy #Allergy #Alzheimer's #Biotech #China #Clinical trial #Eli Lilly #Obesity #Osteoarthritis #Spinogenix

This week in Drug Discovery (8 – 12 December) 

News round-up for 8 – 12 December by Bruno Quinney, Content Team at DDW.  This week in DDW, innovative treatments have been developed for neurodegenerative diseases, allergies and arthritis. Elsewhere, China is becoming the dominant force in the biotech sector.  The top stories:   … Read More

#News

#Biomedical research #Eli Lilly #Laboratory #Meet the Researcher

Meet the researcher: Catherine Whittington, Associate Professor

DDW’s Diana Turner speaks to Catherine Whittington, Associate Professor in the Department of Biomedical Engineering at WPI, about her current work and the research that drives her.   DT: Can you tell us what you do and what you’re working on at the moment? CW: I teach classes in the biomedical engineering (BME)… Read More

#Exclusive Content #Opinion

#Business #Eli Lilly #MeiraGTx #Ophthalmology

MeiraGTx partners with Eli Lilly in ophthalmology 

Genetic medicines company MeiraGTx has announced a strategic partnership with Eli Lilly to develop and commercialise genetic medicines in ophthalmology.  The deal, worth $475 million, will see MeiraGTx grant Lilly worldwide exclusive rights to its AAV-AIPL1 programme for treatment of Leber congenital amaurosis 4 (LCA4). LCA4 is one of the… Read More

#Business & Investment #News

Female researcher in a laboratory
#Artificial intelligence (AI) #Drug discovery #Eli Lilly #Insilico Medicine

Insilico partners with Eli Lilly on AI drug discovery 

Drug discovery company Insilico Medicine has entered a research collaboration with pharmaceutical giant Eli Lilly to advance AI-driven drug discovery.  Insilico will use its validated Pharma.AI platform to generate, design, and optimise candidate compounds against targets defined under the agreement.   The company is eligible to receive over $100 million including… Read More

#Business & Investment #News

#Breast cancer #Cancer research #Eli Lilly

Abemaciclib results offer hope for breast cancer treatment

Pharmaceutical company Eli Lilly has announced encouraging results from the Phase III trial of its Verzenio (abemaciclib) treatment for breast cancer.   The data shows that two years of adjuvant abemaciclib plus endocrine therapy (ET) reduced the risk of death from breast cancer by 15.8% versus… Read More

#News

Breast cancer
#Breast cancer #Eli Lilly #FDA #Gene mutation #Oncology

FDA approves Inluriyo in ER+, HER2-, ESR1-mutated breast cancer

The US Food and Drug Administration (FDA) has approved Eli Lilly’s Inluriyo (imlunestrant, 200mg tablets), an oral oestrogen receptor antagonist.  It is approved for the treatment of adults with oestrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2–), ESR1-mutated advanced or metastatic breast cancer (MBC) whose disease progressed after… Read More

#News #Regulatory #Trending News

Drugs targeting amyloid Plaque
#Alzheimer's #Eli Lilly #European Commission #Neurodegenerative disorders #Neuroscience

European Commission extends EU use of Lilly’s donanemab

The European Commission (EC) has granted marketing authorisation for Lilly’s Kisunla (donanemab) in early symptomatic Alzheimer's disease (AD).  It is approved in adults with mild cognitive impairment as well as those with mild dementia stages of AD with confirmed amyloid pathology who are apolipoprotein E (ApoE4) heterozygotes or non-carriers.  "Kisunla… Read More

#News #Regulatory

Mounjaro
#Cardiovascular disease #Diabetes #Eli Lilly #GLP-1 #Obesity

Mounjaro comes out on top in head-to-head trial

Lilly has shared topline results from SURPASS-CVOT, a head-to-head Phase III cardiovascular outcomes trial comparing two incretin therapies in adults with type 2 diabetes and established atherosclerotic cardiovascular disease.   Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, was compared to Trulicity (dulaglutide), a GLP-1 receptor agonist that showed… Read More

#News

Gene editing
#Eli Lilly #Gene editing #Gene therapy #Mergers and acquisitions #Verve Therapeutics

Lilly to acquire gene editing specialists Verve Therapeutics

Eli Lilly and Verve Therapeutics have announced a definitive agreement for Lilly to acquire Verve.  Verve is developing a pipeline of gene editing medicines designed to address the drivers of atherosclerotic cardiovascular disease (ASCVD) through treatments that may only need to be given once in a lifetime.   Verve's lead programme… Read More

#Business & Investment #News

RNA
#Collaboration #Eli Lilly #Gene therapy #Hearing Loss #RNA

Lilly and Rznomics agree $1.3 billion RNA-editing deal

Eli Lilly has entered into an agreement to develop and commercialise novel RNA-editing therapies using Rznomics' proprietary trans-splicing ribozyme platform.  Rznomics is a clinical-stage biopharmaceutical company based in South Korea focused on developing RNA-based gene therapies.  The collaboration focuses on the discovery and development of RNA-editing therapeutics for sensorineural hearing… Read More

#Business & Investment #News

#Alchemab Therapeutics #Amyotrophic lateral sclerosis (ALS) #Dementia #Eli Lilly #Neuroscience

ALS drug licensing agreement confirmed

Alchemab Therapeutics has entered into a licensing agreement with Eli Lilly and Company (Lilly) for ATLX-1282, Alchemab’s first-in-class IND-ready programme for amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions. The transaction is worth up to a total of $415 million, including an undisclosed upfront payment, potential discovery, development, and commercialisation… Read More

#Business & Investment #News

#Diabetes #Eli Lilly #GLP-1 #Phase III trial

Lilly’s oral GLP-1 first to complete a Phase III trial

Eli Lilly has announced positive topline Phase III results from ACHIEVE-1, evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes and inadequate glycaemic control with diet and exercise alone.   Orforglipron is the first oral small molecule glucagon-like peptide-1 (GLP-1) receptor… Read More

#Editor's Choice #News